Isosorbide mononitrate is an organic nitrate with vasodilating properties. It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. Isosorbide mononitrate is an active metabolite of isosorbide dinitrate. Like other organic nitrates, isosorbide mononitrate acts as a prodrug for its active metabolite, nitric oxide, which mediates the therapeutic action of isosorbide mononitrate. Isosorbide mononitrate has a longer duration of action than nitroglycerin due to its slow onset of absorption and metabolism.
First approved by the FDA in 1991, isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of orally-administered isosorbide mononitrate is not rapid enough to offset an acute anginal episode. It is available in oral tablets generically and under the brand name ISMO and Monoket. The extended-release forms of the drug are also available generically and under the brand name Imdur.
Isosorbide mononitrate is indicated for the prevention and management of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid to be useful in aborting an acute anginal episode.
Ahmed Samy, Giza, Egypt
The University Of Texas Health Science Center at Houston, Houston, Texas, United States
Ain Shams maternity hospital, Cairo, Egypt
faculty of medicine - Cairo university, Cairo, Kasr El Ainy, Egypt
Qingyuan People's Hospital, Qingyuan, China
faculty of medicine - Kafr Elsheikh university, Kafr Ash Shaykh, Egypt
Royal Infirmary, Edinburgh, Lothian, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.